AS8351
Based on 1 publication(s) in Google Scholar
AS8351 (NSC51355) is a KDM5B inhibitor, which can induce and sustain active chromatin marks to facilitate the induction of cardiomyocyte-like cells.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.88%
- CAS No.: 796-42-9
- 화학식: C17H13N3O2
- 분자량:291.30
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Transcription Factor-Targeted Library
HY-L090
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Cysteine Targeted Covalent Library
HY-L153
-
Bioactive Compound Library Max
HY-L181
-
Epigenetics Compound Library Mini
HY-L005M
-
Bioactive Compound Library
HY-L001
-
Methylation Compound Library
HY-L203
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) AS8351
More
Biological Activity
|
KDM5 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
2.2 μM
Compound: NIH
|
Antiproliferative activity at human A549 cells after 72 hrs by MTT assay
Antiproliferative activity at human A549 cells after 72 hrs by MTT assay
|
[PMID: 22861499] |
| DMS-53 | IC50 |
1.1 μM
Compound: NIH
|
Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay
Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay
|
[PMID: 22861499] |
| HEL | EC50 |
0.06 μg/mL
Compound: 7
|
Antiviral activity against Human herpesvirus 1 strain KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Human herpesvirus 1 strain KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| HEL | EC50 |
0.14 μg/mL
Compound: 7
|
Antiviral activity against Vaccinia virus infected human HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Vaccinia virus infected human HEL cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| HEL | EC50 |
0.4 μg/mL
Compound: 7
|
Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| HEL | EC50 |
0.4 μg/mL
Compound: 7
|
Antiviral activity against TK(-) aciclovir-resistant Human herpesvirus 1 strain KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against TK(-) aciclovir-resistant Human herpesvirus 1 strain KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| HeLa | EC50 |
>0.04 μg/mL
Compound: 7
|
Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| HeLa | EC50 |
>0.04 μg/mL
Compound: 7
|
Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| HeLa | EC50 |
>0.04 μg/mL
Compound: 7
|
Antiviral activity against Vesicular stomatitis virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Vesicular stomatitis virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| HUVEC | IC50 |
20.1 μM
Compound: 311
|
Antiproliferative activity against HUVEC after 22 to 72 hrs by MTT assay
Antiproliferative activity against HUVEC after 22 to 72 hrs by MTT assay
|
[PMID: 27187862] |
| MRC5 | IC50 |
>10 μM
Compound: NIH
|
Antiproliferative activity at human MRC5 cells after 72 hrs by MTT assay
Antiproliferative activity at human MRC5 cells after 72 hrs by MTT assay
|
[PMID: 22861499] |
| MT4 | CC50 |
0.1 μg/mL
Compound: 7
|
Cytotoxicity against Homo sapiens (human) MT4 cells
Cytotoxicity against Homo sapiens (human) MT4 cells
|
10.1007/s00044-011-9662-9 |
| MT4 | EC50 |
>0.1 μg/mL
Compound: 7
|
Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| MT4 | EC50 |
>0.1 μg/mL
Compound: 7
|
Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| SK-N-MC | IC50 |
0.3 μM
Compound: NIH
|
Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
|
[PMID: 19601577] |
| SK-N-MC | IC50 |
0.3 μM
Compound: NIH
|
Antiproliferative activity against human SK-N-MC cells
Antiproliferative activity against human SK-N-MC cells
|
[PMID: 19601577] |
| SK-N-MC | IC50 |
0.5 μM
Compound: 311
|
Antiproliferative activity against human SK-N-MC cells after 22 to 72 hrs by MTT assay
Antiproliferative activity against human SK-N-MC cells after 22 to 72 hrs by MTT assay
|
[PMID: 27187862] |
| SK-N-MC | IC50 |
0.5 μM
Compound: H2NIH (311)
|
Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
|
[PMID: 19216562] |
| SK-N-MC | IC50 |
0.59 μM
Compound: H2NIH
|
Antiproliferative activity against human SK-N-MC cells by MTT assay
Antiproliferative activity against human SK-N-MC cells by MTT assay
|
[PMID: 17963372] |
| SK-N-MC | IC50 |
0.71 μM
Compound: NIH
|
Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
|
[PMID: 17602603] |
| SK-N-MC | IC50 |
1 μM
Compound: NIH
|
Antiproliferative activity against human SK-N-MC cells after 96 hrs by MTT assay
Antiproliferative activity against human SK-N-MC cells after 96 hrs by MTT assay
|
[PMID: 19601577] |
| SK-N-MC | IC50 |
1.1 μM
Compound: NIH
|
Antiproliferative activity at human SK-N-MC cells after 72 hrs by MTT assay
Antiproliferative activity at human SK-N-MC cells after 72 hrs by MTT assay
|
[PMID: 22861499] |
| SK-N-MC | IC50 |
1.3 μM
Compound: 311
|
Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
|
[PMID: 22858101] |
| SK-N-MC | IC50 |
2.53 μM
Compound: NIH
|
Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTS assay
Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTS assay
|
[PMID: 21846118] |
| SK-N-MC | IC50 |
2.53 μM
Compound: NIH
|
Cytotoxicity against human SK-N-MC cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human SK-N-MC cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 23276209] |
| Vero | EC50 |
>0.8 μg/mL
Compound: 7
|
Antiviral activity against Human coxsackievirus B4 infected Vero cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Human coxsackievirus B4 infected Vero cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| Vero | EC50 |
>0.8 μg/mL
Compound: 7
|
Antiviral activity against Human parainfluenza virus 3 infected Vero cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Human parainfluenza virus 3 infected Vero cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| Vero | EC50 |
>0.8 μg/mL
Compound: 7
|
Antiviral activity against Mammalian orthoreovirus 1 infected Vero cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Mammalian orthoreovirus 1 infected Vero cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| Vero | EC50 |
>0.8 μg/mL
Compound: 7
|
Antiviral activity against Punta Toro virus infected Vero cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Punta Toro virus infected Vero cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
| Vero | EC50 |
>0.8 μg/mL
Compound: 7
|
Antiviral activity against Sindbis virus infected Vero cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against Sindbis virus infected Vero cells assessed as inhibition of virus-induced cytopathicity
|
10.1007/s00044-011-9662-9 |
AS8351 affects epigenetic modifications by competing with α-ketoglutarate (α-KG) for chelating iron [Fe(II)] in certain epigenetic enzymes, such as the JmjC domain-containing histone demethylases (JmjC-KDMs) that require α-KG and iron as co-factors[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 796-42-9
-
Appearance Solid
-
분자량 291.30
-
화학식 C17H13N3O2
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CC=NC=C1)N/N=C/C2=C3C=CC=CC3=CC=C2O
-
Synonyms
NSC51355
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Clin Exp Med
Corin: a dual inhibitor for KDM1A/HDAC1, suppresses hepatocellular carcinoma by triggering cuproptosis. [Abstract]2025 Nov 25;26(1):33. PMID: 41286164
용액&용해도
DMSO : 150 mg/mL (514.93 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.58 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Liu K, et al. Chemical Modulation of Cell Fate in Stem Cell Therapeutics and Regenerative Medicine. Cell Chem Biol. 2016 Aug 18;23(8):893-916. [Content Brief]
[2]. Cao N, et al. Conversion of human fibroblasts into functional cardiomyocytes by small molecules. Science. 2016 Jun 3;352(6290):1216-20. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4329 mL | 17.1644 mL | 34.3289 mL | 85.8222 mL |
| 5 mM | 0.6866 mL | 3.4329 mL | 6.8658 mL | 17.1644 mL | |
| 10 mM | 0.3433 mL | 1.7164 mL | 3.4329 mL | 8.5822 mL | |
| 15 mM | 0.2289 mL | 1.1443 mL | 2.2886 mL | 5.7215 mL | |
| 20 mM | 0.1716 mL | 0.8582 mL | 1.7164 mL | 4.2911 mL | |
| 25 mM | 0.1373 mL | 0.6866 mL | 1.3732 mL | 3.4329 mL | |
| 30 mM | 0.1144 mL | 0.5721 mL | 1.1443 mL | 2.8607 mL | |
| 40 mM | 0.0858 mL | 0.4291 mL | 0.8582 mL | 2.1456 mL | |
| 50 mM | 0.0687 mL | 0.3433 mL | 0.6866 mL | 1.7164 mL | |
| 60 mM | 0.0572 mL | 0.2861 mL | 0.5721 mL | 1.4304 mL | |
| 80 mM | 0.0429 mL | 0.2146 mL | 0.4291 mL | 1.0728 mL | |
| 100 mM | 0.0343 mL | 0.1716 mL | 0.3433 mL | 0.8582 mL |
AS8351 Related Classifications
HY-100744 Related Classifications
Powered by Bioz